Telomir Pharmaceuticals Submits IND for TNBC Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Source: Newsfilter
- IND Submission: Telomir Pharmaceuticals has submitted an Investigational New Drug application to the FDA for its lead candidate, Telomir-1, targeting advanced and metastatic Triple-Negative Breast Cancer (TNBC), marking a critical transition from preclinical proof-of-concept to clinical development.
- Clinical Trial Plan: Subject to IND clearance, the company plans to initiate a Phase 1/2 clinical trial to evaluate Telomir-1 as an oral monotherapy, utilizing a standard 3+3 dose-escalation design to assess safety and preliminary antitumor activity, focusing on determining the recommended Phase 2 dose.
- Preclinical Findings: Telomir-Zn demonstrated significant tumor growth reduction and decreased metastatic dissemination across various TNBC models, showing iron-dependent tumor cell mortality in chemotherapy-resistant settings, indicating its potential efficacy in treatment.
- Market Opportunity: Triple-Negative Breast Cancer accounts for 10-15% of all breast cancer cases, with limited treatment options available, creating a substantial unmet need for more effective and durable therapies, and the successful development of Telomir-Zn could significantly improve patient outcomes and reshape the treatment landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TELO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TELO
About TELO
Telomir Pharmaceuticals, Inc. is a biotechnology company developing small-molecule therapeutics designed to target epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The Company's lead candidate, Telomir-1 (Telomir-Zn), is an investigational therapy that has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, epigenetic regulation, mitochondrial function, and genomic stability. Telomir-1 is an oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help protect against age related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease, and Age-related Macular Degeneration (AMD), as well as Type 2 diabetes, breast cancer, and Alzheimer’s disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Telenor Acquires Enivest for NOK 2.5 Billion
- Acquisition Scale: Telenor has agreed to acquire Enivest for NOK 2.5 billion, a leading fiber operator in Western Norway, which will enhance Telenor's market position and further its expansion strategy in the Norwegian broadband market.
- Customer Service Enhancement: Through this acquisition, Enivest's customers will gain access to a broader range of digital security and entertainment services offered by Telenor, which is expected to improve customer satisfaction and strengthen market competitiveness.
- Financial Performance and Growth Potential: Enivest reported revenues of approximately NOK 290 million and EBITDA of around NOK 130 million in 2025, with a projected EBITDA growth of 12% for 2026, laying a solid foundation for increased cash flow going forward.
- Integration and Investment Plans: Telenor plans to invest approximately NOK 150 million in integration and network upgrades, expecting to realize significant synergies through cross-selling and an expanded product portfolio, thereby enhancing operational efficiency.
See More
Telomir Pharmaceuticals Receives FDA Approval for Clinical Trial
- FDA IND Approval: Telomir Pharmaceuticals has received FDA clearance for its lead candidate Telomir-Zn, marking a significant step toward clinical evaluation aimed at addressing the urgent needs of patients with advanced triple-negative breast cancer.
- Clinical Trial Design: The planned Phase 1/2 trial, set to initiate in the first half of 2026, will enroll approximately 76 patients using a 3+3 dose escalation design to evaluate the safety, tolerability, and preliminary antitumor activity of Telomir-Zn.
- Biomarker Analysis: The study will incorporate an integrated biomarker program to assess changes in epigenetic regulation and their correlation with clinical outcomes, aiming to identify potential predictive biomarkers to guide future treatment strategies.
- Significant Market Potential: Triple-negative breast cancer accounts for 10-15% of breast cancer cases, and despite limited existing treatment options, the global market presents a multi-billion-dollar opportunity, with Telomir-Zn's development poised to fill this gap.
See More
Telomir Pharmaceuticals Submits IND for TNBC Treatment
- IND Submission: Telomir Pharmaceuticals has submitted an Investigational New Drug application to the FDA for its lead candidate, Telomir-1, targeting advanced and metastatic Triple-Negative Breast Cancer (TNBC), marking a critical transition from preclinical proof-of-concept to clinical development.
- Clinical Trial Plan: Subject to IND clearance, the company plans to initiate a Phase 1/2 clinical trial to evaluate Telomir-1 as an oral monotherapy, utilizing a standard 3+3 dose-escalation design to assess safety and preliminary antitumor activity, focusing on determining the recommended Phase 2 dose.
- Preclinical Findings: Telomir-Zn demonstrated significant tumor growth reduction and decreased metastatic dissemination across various TNBC models, showing iron-dependent tumor cell mortality in chemotherapy-resistant settings, indicating its potential efficacy in treatment.
- Market Opportunity: Triple-Negative Breast Cancer accounts for 10-15% of all breast cancer cases, with limited treatment options available, creating a substantial unmet need for more effective and durable therapies, and the successful development of Telomir-Zn could significantly improve patient outcomes and reshape the treatment landscape.
See More
Coinbase CEO Armstrong Invests in NewLimit, Secures $45 Million Funding
- Company Formation: Coinbase CEO Brian Armstrong's startup NewLimit, founded in 2021, focuses on extending human healthspan by treating age-related diseases, with its latest funding round of $45 million boosting its valuation to $1.62 billion, indicating strong market interest in anti-aging technologies.
- Funding Context: The rapid follow-up funding just five months after its Series B round demonstrates NewLimit's swift growth and investor confidence in the anti-aging sector, with the new capital expected to lay the groundwork for future clinical studies that could advance its technological capabilities.
- Intensifying Competition: With OpenAI CEO Sam Altman investing $180 million in Retro Biosciences, the race to develop technologies that extend human lifespan is heating up, reflecting significant market attention and potential economic returns in this burgeoning field.
- Market Reaction: Despite a downturn in anti-aging research stocks in 2025, NewLimit's successful funding round showcases investor confidence in its long-term potential, which may attract further capital into this emerging market.
See More
Friday's Underperformers: Pharmaceutical, Oil, and Gas Exploration & Production Shares
Market Performance: Oil and gas exploration and production shares are down approximately 1.6%, with Venture Global experiencing a significant drop of about 19.6% and Amplify Energy down by about 5.5%.
Sector Laggards: The decline in oil and gas stocks is highlighted as part of the broader market trends, alongside other sectors such as pharmaceuticals.
See More
Stock Market Update: Dow Jones and Nasdaq Futures Decline as Trade Deficit Data Release is Postponed Due to Shutdown—Trilogy Metals, AMD, and Applovin Under Scrutiny
U.S. Stock Market Update: U.S. stock futures declined following a mixed performance on Monday, with major indices showing slight decreases. The market is influenced by a deal between Advanced Micro Devices and OpenAI, which boosted AI-related stocks.
Government Shutdown Impact: The ongoing government shutdown has delayed the release of U.S. trade deficit data, with President Trump indicating a willingness to collaborate with Democrats on healthcare only after the government reopens.
Key Stock Movements: Trilogy Metals surged 180.38% after a White House investment announcement, while Applovin fell 2.56% amid an SEC investigation. Advanced Micro Devices rose 2.57% due to its deal with OpenAI, and Telomir Pharmaceuticals jumped 30.99% following positive study results.
Economic Outlook: Analysts predict a strong earnings season for Q3 2025, with expectations of low-teens earnings growth for the S&P 500, driven by AI investments and a resilient economy, despite potential tariff pressures.
See More
Telenor Acquires Enivest for NOK 2.5 Billion
- Acquisition Scale: Telenor has agreed to acquire Enivest for NOK 2.5 billion, a leading fiber operator in Western Norway, which will enhance Telenor's market position and further its expansion strategy in the Norwegian broadband market.
- Customer Service Enhancement: Through this acquisition, Enivest's customers will gain access to a broader range of digital security and entertainment services offered by Telenor, which is expected to improve customer satisfaction and strengthen market competitiveness.
- Financial Performance and Growth Potential: Enivest reported revenues of approximately NOK 290 million and EBITDA of around NOK 130 million in 2025, with a projected EBITDA growth of 12% for 2026, laying a solid foundation for increased cash flow going forward.
- Integration and Investment Plans: Telenor plans to invest approximately NOK 150 million in integration and network upgrades, expecting to realize significant synergies through cross-selling and an expanded product portfolio, thereby enhancing operational efficiency.
See More
Telomir Pharmaceuticals Receives FDA Approval for Clinical Trial
- FDA IND Approval: Telomir Pharmaceuticals has received FDA clearance for its lead candidate Telomir-Zn, marking a significant step toward clinical evaluation aimed at addressing the urgent needs of patients with advanced triple-negative breast cancer.
- Clinical Trial Design: The planned Phase 1/2 trial, set to initiate in the first half of 2026, will enroll approximately 76 patients using a 3+3 dose escalation design to evaluate the safety, tolerability, and preliminary antitumor activity of Telomir-Zn.
- Biomarker Analysis: The study will incorporate an integrated biomarker program to assess changes in epigenetic regulation and their correlation with clinical outcomes, aiming to identify potential predictive biomarkers to guide future treatment strategies.
- Significant Market Potential: Triple-negative breast cancer accounts for 10-15% of breast cancer cases, and despite limited existing treatment options, the global market presents a multi-billion-dollar opportunity, with Telomir-Zn's development poised to fill this gap.
See More
Telomir Pharmaceuticals Submits IND for TNBC Treatment
- IND Submission: Telomir Pharmaceuticals has submitted an Investigational New Drug application to the FDA for its lead candidate, Telomir-1, targeting advanced and metastatic Triple-Negative Breast Cancer (TNBC), marking a critical transition from preclinical proof-of-concept to clinical development.
- Clinical Trial Plan: Subject to IND clearance, the company plans to initiate a Phase 1/2 clinical trial to evaluate Telomir-1 as an oral monotherapy, utilizing a standard 3+3 dose-escalation design to assess safety and preliminary antitumor activity, focusing on determining the recommended Phase 2 dose.
- Preclinical Findings: Telomir-Zn demonstrated significant tumor growth reduction and decreased metastatic dissemination across various TNBC models, showing iron-dependent tumor cell mortality in chemotherapy-resistant settings, indicating its potential efficacy in treatment.
- Market Opportunity: Triple-Negative Breast Cancer accounts for 10-15% of all breast cancer cases, with limited treatment options available, creating a substantial unmet need for more effective and durable therapies, and the successful development of Telomir-Zn could significantly improve patient outcomes and reshape the treatment landscape.
See More
Coinbase CEO Armstrong Invests in NewLimit, Secures $45 Million Funding
- Company Formation: Coinbase CEO Brian Armstrong's startup NewLimit, founded in 2021, focuses on extending human healthspan by treating age-related diseases, with its latest funding round of $45 million boosting its valuation to $1.62 billion, indicating strong market interest in anti-aging technologies.
- Funding Context: The rapid follow-up funding just five months after its Series B round demonstrates NewLimit's swift growth and investor confidence in the anti-aging sector, with the new capital expected to lay the groundwork for future clinical studies that could advance its technological capabilities.
- Intensifying Competition: With OpenAI CEO Sam Altman investing $180 million in Retro Biosciences, the race to develop technologies that extend human lifespan is heating up, reflecting significant market attention and potential economic returns in this burgeoning field.
- Market Reaction: Despite a downturn in anti-aging research stocks in 2025, NewLimit's successful funding round showcases investor confidence in its long-term potential, which may attract further capital into this emerging market.
See More
Friday's Underperformers: Pharmaceutical, Oil, and Gas Exploration & Production Shares
Market Performance: Oil and gas exploration and production shares are down approximately 1.6%, with Venture Global experiencing a significant drop of about 19.6% and Amplify Energy down by about 5.5%.
Sector Laggards: The decline in oil and gas stocks is highlighted as part of the broader market trends, alongside other sectors such as pharmaceuticals.
See More
Stock Market Update: Dow Jones and Nasdaq Futures Decline as Trade Deficit Data Release is Postponed Due to Shutdown—Trilogy Metals, AMD, and Applovin Under Scrutiny
U.S. Stock Market Update: U.S. stock futures declined following a mixed performance on Monday, with major indices showing slight decreases. The market is influenced by a deal between Advanced Micro Devices and OpenAI, which boosted AI-related stocks.
Government Shutdown Impact: The ongoing government shutdown has delayed the release of U.S. trade deficit data, with President Trump indicating a willingness to collaborate with Democrats on healthcare only after the government reopens.
Key Stock Movements: Trilogy Metals surged 180.38% after a White House investment announcement, while Applovin fell 2.56% amid an SEC investigation. Advanced Micro Devices rose 2.57% due to its deal with OpenAI, and Telomir Pharmaceuticals jumped 30.99% following positive study results.
Economic Outlook: Analysts predict a strong earnings season for Q3 2025, with expectations of low-teens earnings growth for the S&P 500, driven by AI investments and a resilient economy, despite potential tariff pressures.
See More
